This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dame Kate Bingham

Dame Kate Bingham

Name:

Dame Kate Bingham

Organisation:

SV Health Investors

Year elected:

2021

In her 30 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US. Kate played an active role in setting up the Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee. Prior to joining SV, Kate worked for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine stepping down as Chair in December 2020. She was awarded a DBE in the Queen’s Birthday Honours in June 2021.